1. Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep 2022;49:9903-13. [DOI:10.1007/s11033-022-07525-8]

2. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020;20:651-68. [DOI:10.1038/s41577-020-0306-5]

3. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer?. BMC Med 2016;14:1-8. [DOI:10.1186/s12916-016-0623-5]

4. Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer 2019;18:1-4. [DOI:10.1186/s12943-019-1055-6]

5. Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol 2018;9:6. [DOI:10.3389/fphar.2018.00006]

6. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24:541-50. [DOI:10.1038/s41591-018-0014-x]

7. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37. [DOI:10.1038/nm.3394]

8. Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures-a comparison of different types of cancer cell cultures. Arch Med Sci 2018;14:910-9.

9. Zhao Y, Zhang B, Ma Y, Zhao F, Chen J, Wang B, et al. Colorectal Cancer Patient‐Derived 2D and 3D Models Efficiently Recapitulate Inter‐and Intratumoral Heterogeneity. Adv Sci 2022;9:2201539. [DOI:10.1002/advs.202201539]

10. Clevers H. Modeling development and disease with organoids. Cell 2016;165:1586-97. [DOI:10.1016/j.cell.2016.05.082]

11. Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer 2018;18:407-18. [DOI:10.1038/s41568-018-0007-6]

12. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-6. [DOI:10.1126/science.aao2774]

13. Abbasian MH, Sobhani N, Sisakht MM, D'Angelo A, Sirico M, Roudi R. Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine. Stem Cell Rev Rep 2024:1-5. [DOI:10.1007/s12015-024-10805-4]

14. Grönholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Patient-derived organoids for precision cancer immunotherapy. Cancer Res 2021;81:3149-55. [DOI:10.1158/0008-5472.CAN-20-4026]

15. Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and organoid model systems in cancer research. EMBO J 2019;38:e101654. [DOI:10.15252/embj.2019101654]

16. Yuki K, Cheng N, Nakano M, Kuo CJ. Organoid models of tumor immunology. Trends Immunol 2020;41:652-64. [DOI:10.1016/j.it.2020.06.010]

17. Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 2018;174:1586-98. [DOI:10.1016/j.cell.2018.07.009]

18. Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175(7):1972-88.e16. [DOI:10.1016/j.cell.2018.11.021]

19. Dong J, Holthaus D, Peters C, Koster S, Ehsani M, Quevedo-Olmos A, et al. γδ T cell-mediated cytotoxicity against patient-derived healthy and cancer cervical organoids. Front Immunol 2023;14:1281646. [DOI:10.3389/fimmu.2023.1281646]

20. Zhou G, Lieshout R, van Tienderen GS, de Ruiter V, van Royen ME, Boor PP, et al. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. Br J Cancer 2022;127:649-60. [DOI:10.1038/s41416-022-01839-x]

21. Yu L, Li Z, Mei H, Li W, Chen D, Liu L, et al. Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro. Clin Transl Immunol 2021;10:e1248. [DOI:10.1002/cti2.1248]

22. Chakrabarti J, Holokai L, Syu L, Steele NG, Chang J, Wang J, et al. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget 2018;9:37439. [DOI:10.18632/oncotarget.26473]

23. Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer 2019;7:1-4. [DOI:10.1186/s40425-019-0575-3]

24. Sun Y, Revach OY, Anderson S, Kessler EA, Wolfe CH, Jenney A, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature 2023;615:158-67. [DOI:10.1038/s41586-023-05704-6]

25. Recaldin T, Steinacher L, Gjeta B, Harter MF, Adam L, Kromer K, et al. Human organoids with an autologous tissue-resident immune compartment. Nature 2024;633:165-73. [DOI:10.1038/s41586-024-07791-5]

26. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov 2017;7:462-77. [DOI:10.1158/2159-8290.CD-16-1154]

27. Huang H, Pan Y, Huang J, Zhang C, Liao Y, Du Q, et al. Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer. iScience 2023;26:108198. [DOI:10.1016/j.isci.2023.108198]

28. Forsythe SD, Sivakumar H, Erali RA, Wajih N, Li W, Shen P, et al. Patient-specific sarcoma organoids for personalized translational research: unification of the operating room with rare cancer research and clinical implications. Ann Surg Oncol 2022;29:7354-67. [DOI:10.1245/s10434-022-12086-y]

29. Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med 2019;11:eaay2574. [DOI:10.1126/scitranslmed.aay2574]

30. Meng Q, Xie S, Gray GK, Dezfulian MH, Gandarilla O, Li W, et al. Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. J Immunother Cancer 2021;9: e003213. [DOI:10.1136/jitc-2021-003213]

31. Holokai L, Chakrabarti J, Broda T, Chang J, Hawkins JA, Sundaram N, et al. Increased programmed death-ligand 1 is an early epithelial cell response to Helicobacter pylori infection. PLoS Pathog 2019;15:e1007468. [DOI:10.1371/journal.ppat.1007468]

32. Dijkstra KK, Monkhorst K, Schipper LJ, Hartemink KJ, Smit EF, Kaing S, et al. Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. Cell Rep 2020;31:107588. [DOI:10.1016/j.celrep.2020.107588]

33. Cattaneo CM, Dijkstra KK, Fanchi LF, Kelderman S, Kaing S, van Rooij N, et al. Tumor organoid-T-cell coculture systems. Nat Protoc 2020;15:15-39. [DOI:10.1038/s41596-019-0232-9]

34. Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov 2018;8:1112-29. [DOI:10.1158/2159-8290.CD-18-0349]

35. Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc 2020;15:3380-409. [DOI:10.1038/s41596-020-0379-4]

36. Qian X, Zhao J, Yeung PY, Zhang QC, Kwok CK. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci 2019;44:33-52. [DOI:10.1016/j.tibs.2018.09.012]

37. Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep 2018;24:1363-76. [DOI:10.1016/j.celrep.2018.07.001]

38. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van Den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011;141:1762-72. [DOI:10.1053/j.gastro.2011.07.050]

39. Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science 2019;364:952-5. [DOI:10.1126/science.aaw6985]

40. Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM, Bradshaw CR, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med 2017;23:1424-35.. [DOI:10.1038/nm.4438]